Compare VanEck Gold Miners ETF (GDX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Regeneron Pharmaceuticals Inc — how do they compare? VanEck Gold Miners ETF trades at $90.66, while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while VanEck Gold Miners ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| GDX | REGN | |
|---|---|---|
52-Week High | $115.84 | $812.27 |
52-Week Low | $56.60 | $555.51 |
Market Cap | — | $83.19B |
Sector | — | Health |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $89.84, up 7.09% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's rally and strong miner earnings, though financial ratios are unavailable. The ETF offers diversified exposure to gold mining equities, benefiting from high gold prices and institutional interest.
Outlook is positive due to gold's strength and sector momentum, but risks include volatility from gold price swings and competition from physical gold ETFs. Analyst sentiment is mixed, with some seeing value in miners' underperformance relative to gold.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
